Senescence-associated secretory phenotype
Human evidence is visible; an active trial pathway is not yet visible
9 human-evidence records · 0 active trials · 4,097 visible funding records · 4,074 universities
Canadian Patent Publication
METHODS AND COMPOSITIONS FOR ALTERING SENESCENCE ASSOCIATED SECRETORY PHENOTYPE
Source-linked patent metadata for METHODS AND COMPOSITIONS FOR ALTERING SENESCENCE ASSOCIATED SECRETORY PHENOTYPE, including priority, record stage and longevity-topic connections.
Canadian publication snapshot
Application publication visible
This privacy-minimal view describes one official Canadian patent publication. It is not presented as a complete worldwide patent family.
- Representative publication
- CA3142781A1
- Earliest priority
- June 10, 2019
- Latest publication
- December 17, 2020
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
Senescence-associated secretory phenotype88% metadata match
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →